COVID-19 in Pharmaceuticals 2023
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (30 June 2023)
Special Issue Editors
Interests: carbohydrate small molecule synthesis; organic and biomolecular chemistry developments towards new therapeutic approaches for diabetes; Alzheimer’s disease and other amyloid diseases and carbohydrate-based antibiotics
Special Issues, Collections and Topics in MDPI journals
Interests: anticancer drug design; breast cancer; novel antioestrogens; tubulin targeting agents; azetidinones; antioestrogen–drug conjugates; oestrogen receptor; Burkitt's lymphoma; chronic lymphocytic leukaemia
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
COVID-19 (coronavirus disease 2019) concerns the worldwide outbreak of pneumonia and acute respiratory distress syndrome. The exceptionally rapid spread of the disease, which affects any age group, has highlighted the urgent need for prophylactic and curative treatments. Consequently, combatting SARS-CoV-2 has emerged as a tremendous challenge gathering efforts from academia, pharmaceutical companies, hospitals, international organizations, as well as governments and philanthropic associations.
This Special Issue welcomes opinions, brief reports, communications, research articles, and reviews on these treatments.
Keywords: antibodies; antiviral agent; convalescent serum; coronavirus; COVID-19; curative treatment; dietary supplement; immunity; inhibitors; plasma; PCR; prophylactic treatment; protein-based therapy; RNA; SARS-CoV-2; serological test; small molecules; traditional medicine; vaccine; 2019-nCoV
Prof. Dr. Amélia Pilar Rauter
Prof. Dr. Mary J. Meegan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- • antibodies • antiviral agent • convalescent serum • coronavirus • COVID-19 • curative treatment • dietary supplement • immunity • inhibitors • plasma • PCR • prophylactic treatment • protein-based therapy • RNA • SARS-CoV-2 • serological test • small molecules • traditional medicine
